Because RNF113A acts upstream of the alkylation damage repair pathway by recruiting the ASCC complex, we reasoned that an upregulated response to alkylation damage may promote cancer cell tolerance to alkylating agents and explained the impact of SMYD3 in our SCLC and xenograft models. This evidence concerns the gene SMYD3 and cancer.